AbbVie Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
AbbVie Inc. (ABBV) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of 9.80% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-20.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2026-02-20
- AbbVie Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2025 was 9.80%, a 790.91% increase from fiscal 2024.
- AbbVie Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2024 was 1.10%, a 57.14% increase from fiscal 2023.
- AbbVie Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2023 was 0.70%, a 75.00% increase from fiscal 2022.
- AbbVie Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2022 was 0.40%, a 33.33% increase from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | 9.80% 10-K · filed 2026-02-20 | |
| 2024-12-31 | 1.10% 10-K · filed 2026-02-20 | |
| 2023-12-31 | 0.70% 10-K · filed 2026-02-20 | 1.50% 10-K · filed 2024-02-20 |
| 2022-12-31 | 0.40% 10-K · filed 2025-02-14 | 0.60% 10-K · filed 2023-02-17 |
| 2021-12-31 | 0.30% 10-K · filed 2024-02-20 | |
| 2020-12-31 | 7.20% 10-K · filed 2023-02-17 | |
| 2019-12-31 | 1.00% 10-K · filed 2022-02-18 | |
| 2018-12-31 | 1.20% 10-K · filed 2021-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |